We are seeking an early career researcher to run this Twitter feed, promoting #JournalCF content and European #cysticfibrosis Society events/news. This is a voluntary role. To apply, please DM a CV and a letter of interest/qualifications by 31st January.

Seeking applications for an Administrative & Communication Assistant. It is a full time position, split equally between #cysticfibrosis Europe and the ECFS patient registry. Deadline for applications is 1st February 2020. For more information, visit cf-europe.eu/2019/12/cfe-is-…

The Second Announcement of the #ECFS2020 #cysticfibrosis Conference in Lyon is available: ow.ly/fnz550xQ8Oz

#JournalCF Letter to the Editor explores the utility of n-of-1 trials to expand access to CFTR modulators for rare #cysticfibrosis mutations. ow.ly/NRS450xOcee

To foster basic and translational research on #cysticfibrosis, a number of European Post-Doctoral 2-year duration Research Fellowships will be supported the ECFS and CF Europe. More information on: ow.ly/rCGF50xQ8NF

#openaccess publication in #JournalCF on how rescue of #cysticfibrosis W1282X-CFTR requires inhibition of nonsense mediated decay alongside corrector and potentiator therapy. ow.ly/PNNG50xObUz

The abstract submission deadline for the ECFS #cysticfibrosis Basic Science Conference is this Friday 10 January 23:59 (CET)!! Submit your abstract here ecfs.eu/portugal2020/abstrac…

Data from a recent #JournalCF manuscript finds strong toll-like receptor responses in #cysticfibrosis patients are associated with higher lung function. ow.ly/dWVL50xObGQ

Read in #JournalCF an #openaccess review of intestinal organoid models for #cysticfibrosis research. ow.ly/e2ZL50xObzC

Also #openaccess in #JournalCF, alterations of bone microarchitecture and composition at birth in #cysticfibrosis pigs suggest bone defects may be a primary aspect of disease. ow.ly/xFKF50xObrF

An #openaccess #JournalCF publication on use of ivacaftor in #cysticfibrosis with residual function: Lung function results from an N-of-1 study. ow.ly/d1pr50xOba3

Published in #JournalCF is new evidence demonstrating the utility of lung clearance index as an effective primary endpoint in #cysticfibrosis phase III clinical trial. ow.ly/BaLp50xCPYF

#JournalCF Letter to the Editor - positive clinical outcomes following ivacaftor treatment of #cysticfibrosis genotype 3272–26A > G/Q493X. ow.ly/lyYN50xCPPu

Read results from a survey of #cysticfibrosis community and clinicians about treatment withdrawal research to reduce treatment burden. #JournalCF ow.ly/y9pF50xCPNN

New evidence is emerging that has to be considered as an additional opportunistic pathogen in #cysticfibrosis. Read further in #JournalCF. ow.ly/WsQ950xCPM4

Read a review of the new insights gained into how small molecules for #cysticfibrosis can rescue CFTR structure and function. #JournalCF ow.ly/eCZI50xCPBe

New #JournalCF study asks - Can exercise replace airway clearance techniques in #cysticfibrosis? A survey of patients and healthcare professionals. ow.ly/fIwe50xCPxQ

#JournalCF study used a questionnaire to summarise the lived experience of #cysticfibrosis treatment burden and suggest research themes aimed at reducing burden. ow.ly/9ZhX50xCPwQ

Intestinal organoids function varied between #cysticfibrosis subjects with homozygous F508del, correlates with pulmonary and nutritional parameters and may underly clinical heterogeneity. #JournalCF ow.ly/9NzJ50xCPvV

#CFResearchNews: Could quality improvement programs improve adherence to #cysticfibrosis related diabetes screening and management guidelines? ow.ly/UWAS50xCRND